A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.

Sandip Pravin PatelEdward MayersonYoung Kwang ChaeJonathan StrosbergJue WangBhavana KondaJourdain HaywardChristine M McLeodHelen X ChenElad SharonMegan OthusChristopher W RyanMelissa PletsCharles D BlankeRazelle Kurzrock

Published in: Cancer (2021)

Ipilimumab plus nivolumab demonstrated a 26% ORR in patients with high-grade neuroendocrine neoplasms, with durable responses seen in patients with refractory disease.

Keyphrases

high grade
phase ii
low grade
clinical trial
open label
phase iii
placebo controlled
double blind
study protocol
randomized controlled trial